NASDAQ:PTI - Proteostasis Therapeutics Stock Price, Price Target & More

Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."

Proteostasis Therapeutics Inc. (NASDAQ:PTI) released its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.56) EPS for the quarter, topping the Zacks' consensus estimate of ($0.72) by $0.16. The company had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.38 million. Proteostasis Therapeutics had a negative return on equity of 105.53% and a negative net margin of 1,112.75%. View Proteostasis Therapeutics' Earnings History.

4 equities research analysts have issued 1-year target prices for Proteostasis Therapeutics' stock. Their predictions range from $8.00 to $25.00. On average, they anticipate Proteostasis Therapeutics' share price to reach $14.75 in the next year. View Analyst Ratings for Proteostasis Therapeutics.

Proteostasis Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totalling 3,189,620 shares, an increase of 249.8% from the February 28th total of 911,789 shares. Based on an average trading volume of 6,362,351 shares, the days-to-cover ratio is currently 0.5 days. Approximately 14.6% of the shares of the stock are sold short.

Some companies that are related to Proteostasis Therapeutics include Strongbridge Biopharma (SBBP), Catalyst Biosciences (CBIO), Merus (MRUS), Kadmon (KDMN), Durect (DRRX), Seres Therapeutics (MCRB), BioSpecifics Technologies (BSTC), AVEO Pharmaceuticals (AVEO), Celyad (CYAD), Zymeworks (ZYME), Arbutus Biopharma (ABUS), Aquinox Pharmaceuticals (AQXP), Avadel Pharmaceuticals (AVDL), Savara (SVRA), Selecta Biosciences (SELB), Minerva Neurosciences (NERV), Syndax Pharmaceuticals (SNDX) and Kindred Biosciences (KIN).

(PTI) raised $51 million in an initial public offering on Thursday, February 11th 2016. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

Media stories about PTI stock have been trending somewhat positive this week, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Proteostasis Therapeutics earned a media sentiment score of 0.02 on Accern's scale. They also assigned news headlines about the company an impact score of 46.28 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PTI stock can currently be purchased for approximately $5.12.

Proteostasis Therapeutics has a market capitalization of $174.83 million and generates $5.34 million in revenue each year. The company earns $-59,430,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Proteostasis Therapeutics employs 52 workers across the globe.

Proteostasis Therapeutics' mailing address is 200 TECHNOLOGY SQUARE 4th FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-225-0096 or via email at [email protected]